1
|
Mallart E, Guerin F, Amoura A, Le Scouarnec M, Hamon A, El Meouche I, Chau F, Lefort A, Fantin B, Cattoir V, de Lastours V. Impact of the phenotypic expression of temocillin resistance in Escherichia coli on temocillin efficacy in a murine peritonitis model. J Antimicrob Chemother 2024; 79:1051-1059. [PMID: 38501355 DOI: 10.1093/jac/dkae072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 02/29/2024] [Indexed: 03/20/2024] Open
Abstract
BACKGROUND Temocillin is a narrow spectrum β-lactam active against MDR Enterobacterales. Mechanisms of acquired resistance to temocillin are poorly understood. We analysed resistance mechanisms in clinical isolates of Escherichia coli and evaluated their impact on temocillin efficacy in vitro and in a murine peritonitis model. METHODS Two sets of isogenic clinical E. coli strains were studied: a susceptible isolate (MLTEM16S) and its resistant derivative, MLTEM16R (mutation in nmpC porin gene); and temocillin-resistant derivatives of E. coli CFT073: CFT-ΔnmpC (nmpC deletion), CFTbaeS-TP and CFTbaeS-AP (two different mutations in the baeS efflux-pump gene).Fitness cost, time-kill curves and phenotypic expression of resistance were determined. Temocillin efficacy was assessed in a murine peritonitis model. RESULTS MICs of temocillin were 16 and 64 mg/L for MLTEM16S and MLTEM16R, respectively, and 8, 128, 256 and 256 mg/L for E. coli-CFT073, CFT-ΔnmpC, CFTbaeS-TP and CFTbaeS-AP, respectively. No fitness cost of resistance was evidenced. All resistant strains showed heteroresistant profiles, except for CFTbaeS-AP, which displayed a homogeneous pattern. In vitro, temocillin was bactericidal against MLTEM16R, CFT-ΔnmpC, CFTbaeS-TP and CFTbaeS-AP at 128, 256, 512 and 512 mg/L, respectively. In vivo, temocillin was as effective as cefotaxime against MLTEM16R, CFT-ΔnmpC and CFTbaeS-TP, but inefficient against CFTbaeS-AP (100% mortality). CONCLUSIONS Heteroresistant NmpC porin alteration and active efflux modification do not influence temocillin efficacy despite high MIC values, unfavourable pharmacokinetic/pharmacodynamic conditions and the absence of fitness cost, whereas homogeneously expressed BaeS efflux pump alteration yielding similar MICs leads to temocillin inefficacy. MIC as sole predictor of temocillin efficacy should be used with caution.
Collapse
Affiliation(s)
- Elise Mallart
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
| | - François Guerin
- UMR1230, INSERM and Université Rennes 1, F-35043 Rennes, France
- Service de Bactériologie-Hygiène Hospitalière & CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), CHU Pontchaillou, F-35033 Rennes, France
| | - Ariane Amoura
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
| | - Matthieu Le Scouarnec
- Service de Bactériologie-Hygiène Hospitalière & CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), CHU Pontchaillou, F-35033 Rennes, France
| | - Antoine Hamon
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
| | - Imane El Meouche
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
| | - Françoise Chau
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
| | - Agnès Lefort
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
- Service de Médecine Interne, Hôpital Beaujon, AP-HP, Université Paris Cité, F-92210 Clichy, France
| | - Bruno Fantin
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
- Service de Médecine Interne, Hôpital Beaujon, AP-HP, Université Paris Cité, F-92210 Clichy, France
| | - Vincent Cattoir
- UMR1230, INSERM and Université Rennes 1, F-35043 Rennes, France
- Service de Bactériologie-Hygiène Hospitalière & CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), CHU Pontchaillou, F-35033 Rennes, France
| | - Victoire de Lastours
- IAME Research Group, UMR1137 INSERM and Uiversité Paris Cité, F-75018 Paris, France
- Service de Médecine Interne, Hôpital Beaujon, AP-HP, Université Paris Cité, F-92210 Clichy, France
| |
Collapse
|
2
|
Pharmacodynamics of Temocillin in Neutropenic Murine Infection Models. Antimicrob Agents Chemother 2023; 67:e0143322. [PMID: 36692307 PMCID: PMC9933716 DOI: 10.1128/aac.01433-22] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Temocillin is used for the treatment of various infections caused by Enterobacterales. The pharmacokinetic (PK)/pharmacodynamic (PD) index that is best correlated with the activity of beta-lactams is the percentage of time that the unbound concentration exceeds the MIC (%fT>MIC). However, the %fT>MIC needed for a bacteriostatic or killing effect of temocillin is unknown in thigh and lung infection models. In the present study, we studied the temocillin PK in plasma and epithelial lining fluid (ELF) of infected neutropenic mice and determined the plasma exposure-response relationships for Escherichia coli and Klebsiella pneumoniae. Neutropenic murine thigh and lung infection models were used. The bacterial loads in the thighs or lungs were determined. A sigmoid maximum-effect model was used to fit the plasma exposure-response relationship. A one-compartment model with first-order absorption best described temocillin PK (clearance [CL], 1.03 L/h/kg; volume of distribution [V], 0.457 L/kg). Protein binding was 78.2% ± 1.3% across different plasma concentrations. A static effect was achieved for all strains in both the thigh and lung infection models. However, the median %fT>MIC needed for a static effect was much lower in the lung infection model (27.8% for E. coli and 38.2% for K. pneumoniae) than in the thigh infection model (65.2% for E. coli and 64.9% for K. pneumoniae). A 1-log kill was reached for all strains in the lung infection model (median %fT>MIC values of 42.1% for E. coli and 44.1% for K. pneumoniae) and 7 out of 8 strains in the thigh infection model (median %fT>MIC values of 85.4% for E. coli and 74.5% for K. pneumoniae). These data support the use of temocillin in patients with pneumonia.
Collapse
|
3
|
Alexandre K, Caron F. Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study-authors' response. J Antimicrob Chemother 2021; 76:1950-1951. [PMID: 33893503 DOI: 10.1093/jac/dkab129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Kévin Alexandre
- Normandie Univ, UNIROUEN, UNICAEN, GRAM 2.0, Rouen University Hospital, Department of Infectious Disease, F 76000 Rouen, France
| | - François Caron
- Normandie Univ, UNIROUEN, UNICAEN, GRAM 2.0, Rouen University Hospital, Department of Infectious Disease, F 76000 Rouen, France
| |
Collapse
|
4
|
Chawki S, Sokal A, Duprilot M, Henry A, Leflon-Guibout V, Nicolas-Chanoine MH, Fantin B, de Lastours V. Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes. Eur J Clin Microbiol Infect Dis 2021; 40:1773-1777. [PMID: 33609262 DOI: 10.1007/s10096-021-04158-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 01/07/2021] [Indexed: 12/07/2022]
Abstract
With rising antibiotic resistance, alternatives to carbapenems are needed for acute cholangitis (AC). Temocillin reaches high biliary concentrations with limited impact on microbiota. We retrospectively included 140 AC episodes and assessed the efficacy of temocillin using microbiology susceptibility testing from blood cultures. Considering all bacteria collected by episode, resistance to temocillin, PIP/TAZ and 3GC occurred in 27/140 (26%), 32 (22.8%) and 31 (22%) episodes, respectively (p = 0.7). After documentation, temocillin could have spared PIP/TAZ or carbapenems in 14/26 and 4/11 episodes. Temocillin may constitute an alternative treatment after microbiological documentation by sparing carbapenems and/or PIP/TAZ, but not as an empirical therapeutic option.
Collapse
Affiliation(s)
- Sylvain Chawki
- Service de Médecine Interne, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France
| | - Aurélien Sokal
- Service de Médecine Interne, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France
| | - Marion Duprilot
- Laboratoire de Microbiologie, Hôpital Beaujon, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France.,IAME Research Group, UMR 1137, Université de Paris and INSERM, 75018, Paris, France
| | - Amandine Henry
- Service de Médecine Interne, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France
| | - Véronique Leflon-Guibout
- Laboratoire de Microbiologie, Hôpital Beaujon, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France
| | - Marie-Hélène Nicolas-Chanoine
- Laboratoire de Microbiologie, Hôpital Beaujon, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France.,IAME Research Group, UMR 1137, Université de Paris and INSERM, 75018, Paris, France
| | - Bruno Fantin
- Service de Médecine Interne, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France.,IAME Research Group, UMR 1137, Université de Paris and INSERM, 75018, Paris, France
| | - Victoire de Lastours
- Service de Médecine Interne, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, 92100, Clichy, Paris, France. .,IAME Research Group, UMR 1137, Université de Paris and INSERM, 75018, Paris, France.
| |
Collapse
|
5
|
Tsakris A, Koumaki V, Dokoumetzidis A, Balakrishnan I. Monte Carlo simulation of temocillin 6 g daily administered by continuous infusion or intermittent dosage. J Antimicrob Chemother 2020; 75:3079-3080. [PMID: 32642761 DOI: 10.1093/jac/dkaa248] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Athanasios Tsakris
- Department of Microbiology, Medical School, University of Athens, Athens, Greece
| | - Vasiliki Koumaki
- Department of Microbiology, Medical School, University of Athens, Athens, Greece
| | | | - Indran Balakrishnan
- Department of Medical Microbiology, Royal Free London NHS Foundation Trust, London, UK
| |
Collapse
|
6
|
Gudiol C, Cuervo G, Carratalà J. Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Curr Opin Crit Care 2020; 25:438-448. [PMID: 31369411 DOI: 10.1097/mcc.0000000000000646] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW Infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are increasing worldwide. Carbapenems are usually regarded as the antibiotics of choice for the treatment of serious ESBL infections. However, because of the alarming emergence or carbapenem resistance, interest in effective alternatives has emerged. The present review summarizes the findings published on the antibiotics currently available for treatment of patients with an ESBL-E bloodstream infection (BSI). RECENT FINDINGS Meropenem and imipenem are the drugs recommended for treatment of ESBL BSIs in critically ill patients, and in infections with high bacterial loads or elevated β-lactam minimum inhibitory concentrations. Ertapenem should be reserved for patients with less severe presentations, and should be used at high doses. In milder presentations or BSIs from low-risk sources, other carbapenem-sparing alternatives could be considered: cephamycins, fluoroquinolones, and particularly a β-lactam/β-lactam inhibitor combination (particularly piperacillin/tazobactam). Optimized dosing of piperacillin/tazobactam is recommended (high doses and extended infusion). There are few data on the use of the promising newly available drugs (e.g. ceftolozane/tazobactam, ceftazidime/avibactam, cefiderocol, and plazomicin), and it seems reasonable to reserve them as last-resort drugs. SUMMARY Carbapenems should be used in patients with serious infections; alternatives could be used individually, particularly for definitive treatment of patients with milder presentations.
Collapse
Affiliation(s)
- Carlota Gudiol
- Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona.,REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain
| | - Guillermo Cuervo
- Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona.,REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain
| | - Jordi Carratalà
- Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona.,REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|